Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption
Source: SeekingAlpha
2026-05-01 06:02:33 ET
More on Bio-Rad Laboratories, Inc.
- Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
- Bio-Rad Laboratories, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
- Bio-Rad Laboratories, Inc. Non-GAAP EPS of $1.89 misses by $0.10, revenue of $592.1M beats by $3.24M
- Bio-Rad Laboratories, Inc. Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
10.41% G/L:
$274.70 Last:
188,486 Volume:
$274.72 Open:
BIO Latest News
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
